Approval to expand the product matrix to include the 2.25 mm taxusliberte paclitaxel-eluting coronary stent system. this device size will be marketed under thetrade name taxus liberte atom paclitaxel-eluting coronary stent system (monorail and over-the-wire delivery systems), and is indicated for improving luminal diameter for thetreatment of de novo lesions in native coronary arteries > =2.25 mm to <= 4.00 mm in diameter inlesions <= 28 mm in length.